Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Cellular Biomedicine Acquires Rights to CD40LGVAX Vaccine 13
Cellular Biomedicine Acquires CAR-T Immuno-Oncology Technology and Clinical Data from PLA General Hospital 15
Cellular Biomedicine to Acquire Chimeric Antigen Receptor from PersonGen Biomedicine 16
Venture Financing 17
Cellular Biomedicine Raises US$7 Million In Venture Financing 17
Private Equity 18
Sailing Capital Overseas Invests USD30.6 Million in Cellular Biomedicine 18
Partnerships 19
Cellular Biomedicine Enters Into Licensing Agreement With Hsu-Wei Fang For ProCellar 19
Cellular Biomedicine Forms Joint Venture with Thermo Fisher Scientific 20
Cellular Biomedicine Enters Co-Development Agreement with GE Healthcare Life Sciences China 21
Merger 22
EastBridge Investment Group And Cellular Biomedicine Group Complete Merger 22
Licensing Agreements 23
Cellular Biomedicine Enters into Licensing Agreement with National Cancer Institute 23
Novartis Enters into Licensing Agreement with Cellular Biomedicine 24
Cellular Biomedicine Enters into Option Agreement with Augusta University 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
Equity Offering 28
Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 28
Cellular Biomedicine Raises USD14 Million in Private Placement of Shares 29
Cellular Biomedicine to Raise Funds through Public Offering of Shares 30
Cellular Biomedicine to Raise Up to USD50 Million in Issue of Shares 31
Cellular Biomedicine Raises USD19.6 Million in Private Placement of Shares 32
Acquisition 33
Wuhan Dangdai Science & Technology Acquires 19.4% Stake in Cellular Biomedicine for USD43.13 Million 33
Cellular Biomedicine Group Inc – Key Competitors 34
Cellular Biomedicine Group Inc – Key Employees 35
Cellular Biomedicine Group Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Joint Venture 37
Recent Developments 38
Strategy And Business Planning 38
Jun 22, 2018: Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg, Maryland 38
Nov 07, 2017: Cellular Biomedicine Group Opens its New Shanghai GMP Facility and Joint Laboratory 39
Sep 22, 2017: Cellular Biomedicine Group Plans Grand Opening of its New Shanghai Facility 40
Mar 30, 2017: Cellular Biomedicine Group Announces Completion of Wuxi GMP Facility Expansion 41
Jan 03, 2017: Expansion of Cell Production to Produce CAR-T Therapies 42
Financial Announcements 43
Aug 08, 2018: Cellular Biomedicine Group announce second quarter and first half 2018 financial results and business highlights 43
May 08, 2018: Cellular Biomedicine Group Reports First Quarter 2018 Financial Results and Highlights Operational Progress 44
Mar 06, 2018: Cellular Biomedicine Group Reports Full Year 2017 Financial Results 45
Nov 09, 2017: Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Operational Highlights 47
Aug 08, 2017: Cellular Biomedicine Group Reports Second Quarter and First Half 2017 Financial Results and Business Highlights 49
May 08, 2017: Cellular Biomedicine Group Reports First Quarter 2017 Financial Results and Provides Business Highlights 50
Mar 13, 2017: Cellular Biomedicine Group Reports Full-Year 2016 Financial Results and Recent Operational Progress 51
Corporate Communications 53
Jun 20, 2017: Cellular Biomedicine Group Appoints Michael A. Caligiuri, MD as Chair of External Advisory Board 53
Product News 54
05/19/2017: Cellular Biomedicine Group Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting 54
Clinical Trials 55
Jan 09, 2017: Phase I Trial (CALL-1) for C-CAR011 in Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (ALL) in China 55
Other Significant Developments 56
Apr 30, 2018: Cellular Biomedicine Group Announces Results of 2018 Annual Meeting of Stockholders 56
Jan 18, 2018: CBMG Accelerates Cell Therapy Manufacturing with GE Healthcare’s New Start-to-Finish Solution 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellular Biomedicine Group Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cellular Biomedicine Acquires Rights to CD40LGVAX Vaccine 13
Cellular Biomedicine Acquires CAR-T Immuno-Oncology Technology and Clinical Data from PLA General Hospital 15
Cellular Biomedicine to Acquire Chimeric Antigen Receptor from PersonGen Biomedicine 16
Cellular Biomedicine Raises US$7 Million In Venture Financing 17
Sailing Capital Overseas Invests USD30.6 Million in Cellular Biomedicine 18
Cellular Biomedicine Enters Into Licensing Agreement With Hsu-Wei Fang For ProCellar 19
Cellular Biomedicine Forms Joint Venture with Thermo Fisher Scientific 20
Cellular Biomedicine Enters Co-Development Agreement with GE Healthcare Life Sciences China 21
EastBridge Investment Group And Cellular Biomedicine Group Complete Merger 22
Cellular Biomedicine Enters into Licensing Agreement with National Cancer Institute 23
Novartis Enters into Licensing Agreement with Cellular Biomedicine 24
Cellular Biomedicine Enters into Option Agreement with Augusta University 26
NeoStem Enters Into Licensing Agreement With Cellular Biomedicine 27
Cellular Biomedicine Plans to Raise up to USD25.5 Million in Public Offering of Shares 28
Cellular Biomedicine Raises USD14 Million in Private Placement of Shares 29
Cellular Biomedicine to Raise Funds through Public Offering of Shares 30
Cellular Biomedicine to Raise Up to USD50 Million in Issue of Shares 31
Cellular Biomedicine Raises USD19.6 Million in Private Placement of Shares 32
Wuhan Dangdai Science & Technology Acquires 19.4% Stake in Cellular Biomedicine for USD43.13 Million 33
Cellular Biomedicine Group Inc, Key Competitors 34
Cellular Biomedicine Group Inc, Key Employees 35
Cellular Biomedicine Group Inc, Other Locations 36
Cellular Biomedicine Group Inc, Subsidiaries 36
Cellular Biomedicine Group Inc, Joint Venture 37
List of Figures
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cellular Biomedicine Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cellular Biomedicine Group Inc, Medical Devices Deals, 2012 to YTD 2018 10
【免責事項】
http://www.globalresearch.jp/disclaimer